Skip to Content

Join the 'Sunitinib' group to help and get support from people like you.

Sunitinib News

Some Advanced Kidney Cancer Patients May Postpone Treatment

Posted 4 Aug 2016 by Drugs.com

THURSDAY, Aug. 4, 2016 – Not all adults with advanced kidney cancer that has spread require immediate, aggressive treatment, a small new study suggests. "A subset of adults with advanced kidney cancer have slow-growing disease that can be safely managed using active surveillance," explained study lead author Brian Rini, of the Cleveland Clinic's Taussig Cancer Institute. This "watch and wait" approach, instead of active treatment, "could spare them the inconvenience and debilitating side effects of aggressive treatments for about a year, and in some cases several years, without worsening anxiety and depression," Rini said in a news release from The Lancet Oncology. The journal published the findings Aug. 4. In advanced kidney cancer, drugs such as sunitinib and sorafenib are typically used. While they can slow disease progression, they do not cure it, the researchers said. Could some ... Read more

Related support groups: Cancer, Renal Failure, Chronic Kidney Disease, Sutent, Nexavar, Sunitinib, Sorafenib, Wilms' Tumor, Urinary Tract Cancer

Cancer's Heavy Financial Burden

Posted 8 Jun 2016 by Drugs.com

WEDNESDAY, June 8, 2016 – Many cancer patients can't afford to see their doctor or take the medications they've been prescribed, a new study finds. And the problem will likely only get worse as the cost of cancer treatments continues to rise, the study authors said. "You can prescribe the best drug in the world, but if patients can't afford it and they can't get it, then it won't be effective," said study author Dr. Greg Knight. He is chief fellow with the University of North Carolina School of Medicine's division of hematology and oncology. "We saw a significant portion of patients in our study who were stretching their prescriptions or not coming to the doctor's office," Knight said in a university news release. The researchers reviewed survey results from nearly 2,000 patients at the N.C. Cancer Hospital in Chapel Hill, N.C. The participants were all 18 and older, and had been ... Read more

Related support groups: Cancer, Breast Cancer, Prostate Cancer, Lung Cancer, Gleevec, Colorectal Cancer, Votrient, Brain Tumor, Avastin, Tarceva, Melanoma, Skin Cancer, Tasigna, Sutent, Endometrial Cancer, Ovarian Cancer, Sprycel, Afinitor, Herceptin, Nausea/Vomiting - Chemotherapy Induced

U.S. Pays Highest Prices for Cancer Meds: Study

Posted 6 Jun 2016 by Drugs.com

MONDAY, June 6, 2016 – The United States pays the highest prices in the world for generic and brand-name cancer drugs, a new study has found. However, as the world's wealthiest nation, the United States is better able to pay for those pricey drugs than poorer countries with somewhat lower medication prices, added study lead author Dr. Daniel Goldstein. People in China and India are much less able to afford cancer drugs than Americans, he said, even though U.S. monthly drug prices are about three to six times higher in the United States. That doesn't mean America came out on top in overall drug affordability, however. Developed nations such as Australia, England and Israel had the "best deal" in the world on cancer drugs, thanks to government programs that regulate drug pricing, the study found. "America is the wealthiest nation, but its drug prices are significantly higher – so much ... Read more

Related support groups: Cancer, Provera, Depo-Provera, Methotrexate, Breast Cancer, Accutane, Lupron, Tamoxifen, Medroxyprogesterone, Arimidex, Tretinoin, Fluorouracil, Lupron Depot, Femara, Lung Cancer, Gleevec, Colorectal Cancer, Isotretinoin, Rituxan, Claravis

U.S. Oncologists Decry High Cost of Cancer Drugs

Posted 23 Jul 2015 by Drugs.com

THURSDAY, July 23, 2015 – Soaring costs for cancer drugs are hurting patient care in the United States, a group of top oncologists claim. "High cancer-drug prices are affecting the care of patients with cancer and our health care system," Dr. Ayalew Tefferi, a hematologist at Mayo Clinic in Rochester, Minn., said in a Mayo news release. Tefferi and his colleagues made a number of recommendations on how to address the problem in a commentary published July 23 in the Mayo Clinic Proceedings. Allowing Medicare to negotiate drug prices is one of the suggestions the team of 118 leading cancer experts offered as a possible solution. Along with their recommendations, the group also expressed support for a patient-based grassroots movement on change.org that is demanding action on the issue. "The average gross household income in the U.S. is about $52,000 per year. For an insured patient with ... Read more

Related support groups: Cancer, Provera, Depo-Provera, Methotrexate, Breast Cancer, Accutane, Lupron, Prostate Cancer, Tamoxifen, Medroxyprogesterone, Arimidex, Tretinoin, Fluorouracil, Femara, Lupron Depot, Lung Cancer, Gleevec, Colorectal Cancer, Renal Cell Carcinoma, Isotretinoin

Medicines Are Biggest Culprit in Fatal Allergic Reactions: Study

Posted 10 Oct 2014 by Drugs.com

THURSDAY, Oct. 9, 2014 – Although food allergies have garnered a lot of attention lately, a new study reports that medications are actually the biggest cause of sudden deaths related to allergy. Over a little more than a decade, nearly 60 percent of the allergy-related deaths were caused by medications, while less than 7 percent were caused by food allergies, the study found. "Medications can be dangerous," said study researcher Dr. Elina Jerschow, director of the Drug Allergy Center at Montefiore Medical Center and assistant professor of medicine at Albert Einstein College of Medicine, in New York City. While research from other countries has reported medications as a major culprit in anaphylaxis-related deaths, Jerschow said, the problem has been less defined in the United States. One reason is that there is no national registry for anaphylaxis deaths, she said. The study was ... Read more

Related support groups: Provera, Depo-Provera, Amoxicillin, Metronidazole, Doxycycline, Cephalexin, Clindamycin, Penicillin, Bactrim, Methotrexate, Azithromycin, Cipro, Ciprofloxacin, Accutane, Augmentin, Levaquin, Lupron, Flagyl, Keflex, Zithromax

Cancer Chemotherapy Tied to Slight Rise in Risk for Leukemia

Posted 14 Feb 2013 by Drugs.com

THURSDAY, Feb. 14 – Chemotherapy can be a lifesaver for thousands of cancer patients, but a new study suggests that it might slightly raise the odds for a type of leukemia later in life. Over the past 30 years, the risk for acute myeloid leukemia (AML) has increased for patients who underwent chemotherapy for certain forms of cancer, particularly non-Hodgkin lymphoma, the new study found. On the other hand, the researchers from the U.S. National Cancer Institute said other cancer survivors may have a reduced risk for AML due to a change in chemotherapy agents that occurred decades ago. One expert not connected to the study stressed that cancer patients need to put the findings into perspective. "It's important to realize that the risk of developing acute myeloid leukemia related to prior chemotherapy is small and increases with the number of chemotherapy treatments given over time," ... Read more

Related support groups: Cancer, Provera, Depo-Provera, Methotrexate, Accutane, Lupron, Tamoxifen, Medroxyprogesterone, Arimidex, Tretinoin, Fluorouracil, Lupron Depot, Femara, Gleevec, Isotretinoin, Rituxan, Claravis, Votrient, Anastrozole, Avastin

Cancer Drug Doesn't Speed Up Tumor Growth, Researchers Say

Posted 7 Feb 2013 by Drugs.com

THURSDAY, Feb. 7 – The anticancer drug Sutent (sunitinib) does not cause tumors to grow faster after treatment ends, according to a new study. Previous research in animals suggested that tumor growth may accelerate after patients stopped taking Sutent. The new findings, from a study of kidney cancer patients, indicate that the drug does not pose lingering risks for humans. The researchers analyzed data from a phase 3 clinical trial that led to Sutent's approval. They concluded that regardless of how long patients took the drug, it did not cause harm, did not speed up tumor growth and survival was not shortened after treatment ended, according to the findings published online Feb. 7 in the journal Cell Reports. During treatment, Sutent slowed tumor growth and extended patients' lives, the investigators pointed out in a journal news release. Sutent, which is approved for the treatment of ... Read more

Related support groups: Renal Cell Carcinoma, Sutent, Sunitinib

Long-Term Side Effects Key When Cancer Patients Choose Drugs

Posted 4 Jun 2012 by Drugs.com

SATURDAY, June 2 – Long-term medication side effects such as fatigue can be key for patients deciding which cancer drug to take, new research suggests. In the study, people with advanced kidney cancer preferred pazopanib (Votrient) over sunitinib (Sutent), according to a randomized controlled trial funded by the makers of pazopanib. Although doctors may not see a big difference between the two U.S. Food and Drug Administration-approved drugs for the long-term treatment of kidney cancer that has metastasized (spread to other organs), researchers from France found that patients felt Votrient left them less fatigued and with a better quality of life, according to the study. "While we expected patients would prefer one drug over the other, due to the known toxicity profiles, we didn't expect this great a preference," lead study author Dr. Bernard Escudier, a physician at the Institut ... Read more

Related support groups: Cancer, Votrient, Sutent, Pazopanib, Sunitinib

Certain Cancer Drugs May Have Fatal Side Effects: Analysis

Posted 6 Feb 2012 by Drugs.com

MONDAY, Feb. 6 – Treatment with three relatively new cancer drugs may be linked to a slightly increased risk of death, a new analysis suggests. While the risk is low, it should be taken into account by doctors and patients, according to Dana-Farber Cancer Institute scientists and colleagues. The investigators analyzed the findings of 10 clinical trials that included nearly 4,700 patients treated with sorafenib (Nexavar) for kidney and liver cancer; sunitinib (Sutent) for kidney cancer and gastrointestinal stromal tumor; or pazopanib (Votrient) for kidney cancer. These so-called "targeted" drugs are used to stop the growth or spread of cancer by blocking the vascular endothelial growth factor tyrosine kinase receptors in cancer cells, the researchers explained in a Dana-Farber news release. The analysis of the clinical trials revealed that the incidence of fatal complications was 1.5 ... Read more

Related support groups: Votrient, Sutent, Nexavar, Pazopanib, Sunitinib, Sorafenib

Pancreatic Cancer: A Stubborn Foe

Posted 6 Oct 2011 by Drugs.com

THURSDAY, Oct. 6 – The death of Apple Inc. co-founder Steve Jobs has once again focused attention on cancers of the pancreas, which have claimed the lives of several high-profile celebrities. Jobs' tumor was actually one with a better prognosis than the pancreatic cancer that quickly killed actors Michael Landon and Patrick Swayze. In fact, the type of cancer that Jobs had – called neuroendocrine pancreas tumor – afflicts only some 1,000 people a year in the United States, compared to the 40,000 cases of the far more lethal "traditional" pancreatic cancer, the fourth leading cause of cancer death of Americans. Some 50 percent to 60 percent of people with neuroendocrine tumors will be alive five years after their diagnosis, vs. only 5 percent to 10 percent of patients with traditional pancreatic cancer, said Dr. Daniel Labow, chief of surgical oncology at Mount Sinai Hospital in New ... Read more

Related support groups: Pancreatic Cancer, Sutent, Afinitor, Sunitinib, Everolimus, Zortress

Cancer Patients Should Ask Doctors to Use Simple Terms

Posted 28 Sep 2011 by Drugs.com

WEDNESDAY, Sept. 28 – Cancer patients are often faced with many difficult-to-understand treatment choices that can have serious side effects and even mean the difference between life and death. That's why it's crucial that patients insist doctors use plain language in explaining the options, advised Angela Fagerlin, an associate professor of internal medicine at the University of Michigan Medical School and a researcher at the U-M Comprehensive Cancer Center. "People are making life and death decisions that may affect their survival and they need to know what they're getting themselves into. Cancer treatments and tests can be serious. Patients need to know what kind of side effects they might experience as a result of the treatment they undergo," Fagerlin said in a university news release. She and her colleagues outlined a number of tips to help patients get the information they need ... Read more

Related support groups: Cancer, Provera, Depo-Provera, Methotrexate, Breast Cancer, Accutane, Lupron, Prostate Cancer, Tamoxifen, Medroxyprogesterone, Arimidex, Tretinoin, Fluorouracil, Lupron Depot, Femara, Lung Cancer, Gleevec, Colorectal Cancer, Renal Cell Carcinoma, Isotretinoin

Certain Cancer Drugs Don't Interfere With Flu Vaccine: Study

Posted 28 Jun 2011 by Drugs.com

TUESDAY, June 28 – Cancer patients taking the drugs sunitinib and sorafenib respond to the flu vaccine, which suggests that the drugs don't cause as much damage to the immune system as previously believed, researchers say. The small study included 40 volunteers in the Netherlands, including 16 who were treated with sunitinib and six who were treated with sorafenib. Seven patients with metastatic renal cell (kidney) cancer received neither drug, nor did 11 healthy people. When given a flu vaccine, all of the cancer patients had an antibody response similar to that of the healthy participants. The study appears in the current issue of the journal Clinical Cancer Research. "The exact incidence of influenza in patients with cancer is not known, however, it is definitely higher than in the general population," study leader Dr. Carla van Herpen, a medical oncologist at the Radboud University ... Read more

Related support groups: Sutent, Nexavar, Sunitinib, Sorafenib, Influenza Prophylaxis, Influenza Virus Vaccine, H1n1, Inactivated

FDA Approves Sutent for Rare Type of Pancreatic Cancer

Posted 21 May 2011 by Drugs.com

SILVER SPRING, Md., May 20, 2011 /PRNewswire-USNewswire/ – The U.S. Food and Drug Administration today approved Sutent (sunitinib) to treat patients with progressive neuroendocrine cancerous tumors located in the pancreas that cannot be removed by surgery or that have spread to other parts of the body (metastatic). Neuroendocrine tumors found in the pancreas are slow-growing and rare. It is estimated that there are fewer than 1,000 new cases in the United States each year. This is the second new approval by the FDA to treat patients with this disease; on May 5, the agency approved Afinitor (everolimus). "FDA believes it is important to provide cancer patients with as many treatment options as possible," said Richard Pazdur, M.D., director of the Office of Oncology Drug Products in the FDA's Center for Drug Evaluation and Research. "The agency is committed to working with companies to ... Read more

Related support groups: Pancreatic Cancer, Sutent, Sunitinib

Two Experimental Drugs Show Promise for Rare Pancreatic Cancer

Posted 10 Feb 2011 by Drugs.com

WEDNESDAY, Feb. 9 – A pair of tumor-inhibiting drugs more than doubled the progression-free survival time for patients with a rare type of pancreatic cancer, according to two new studies. In separate phase 3 trials by French and American scientists, the drugs everolimus and sunitinib extended the survival of participants with advanced pancreatic neuroendocrine tumors from about five months to 11 months. Also known as islet cell carcinoma, this type of pancreatic cancer represents a small proportion of all such malignancies but has a better prognosis than adenocarcinoma, the more common and deadlier form. Fewer than 20 percent of adenocarcinoma patients are still alive one year after diagnosis, according to the American Cancer Society, while the study authors said the median survival of neuroendocrine patients is 27 months. Both studies were reported in the Feb. 10 issue of the New ... Read more

Related support groups: Pancreatic Cancer, Sutent, Afinitor, Sunitinib, Everolimus, Zortress

Ask a Question

Further Information

Related Condition Support Groups

Renal Cell Carcinoma, Gastrointestinal Stromal Tumor, Pancreatic Cancer

Related Drug Support Groups

Sutent

Sunitinib Patient Information at Drugs.com